Vanguard Group Inc Nuvectis Pharma, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 301,138 shares of NVCT stock, worth $1.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

301,138

Previous 251,138 19.91%

Holding current value

$1.57 Million

Previous $1.59 Million 19.19%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$6.16 - $7.23 $308,000 - $361,500	50,000 Added 19.91%	301,138 $1.89 Million
Q2 2024 Aug 13, 2024	SELL	$5.98 - $8.25 $285,018 - $393,211	-47,662 Reduced 15.95%	251,138 $1.59 Million
Q1 2024 May 10, 2024	BUY	$6.69 - $11.0 $30,218 - $49,687	4,517 Added 1.53%	298,800 $2.45 Million
Q4 2023 Feb 14, 2024	BUY	$7.85 - $11.78 $24,719 - $37,095	3,149 Added 1.08%	294,283 $2.45 Million
Q3 2023 Nov 14, 2023	BUY	$12.89 - $16.29 $324,776 - $410,442	25,196 Added 9.47%	291,134 $3.75 Million
Q2 2023 Aug 14, 2023	BUY	$12.62 - $18.4 $814,053 - $1.19 Million	64,505 Added 32.02%	265,938 $4.25 Million
Q1 2023 May 15, 2023	BUY	$7.32 - $14.37 $41,021 - $80,529	5,604 Added 2.86%	201,433 $2.64 Million
Q4 2022 Feb 10, 2023	BUY	$6.7 - $7.74 $1.13 Million - $1.31 Million	168,768 Added 623.66%	195,829 $1.47 Million
Q3 2022 Nov 14, 2022	BUY	$7.09 - $13.0 $26,970 - $49,452	3,804 Added 16.36%	27,061 $192,000
Q2 2022 Aug 12, 2022	BUY	$7.02 - $20.44 $163,264 - $475,373	23,257 New	23,257 $261,000

Others Institutions Holding NVCT

# of Institutions

Shares Held

1.65M

Call Options Held

Put Options Held

View Full List

About Nuvectis Pharma, Inc.

Ticker NVCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,642,500
Market Cap $76.4M
Description
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...

More about NVCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Nuvectis Pharma, Inc. Transaction History